Key result
Rheumatoid arthritis is linked to higher PON1 levels, with rs662 variants lowering enzyme activity.
Why the study?
Atherosclerosis leading to cardiovascular disease is the main cause of mortality in rheumatoid arthritis patients, and the functional impact of PON1 SNPs rs662 and rs854860 on antioxidative activity remains unclear.
Case-Control (n=1,026)
No
In patients with rheumatoid arthritis, cardiovascular disease correlates with increased PON1 levels but lower PON1 activity, with arylesterase activity identifying phenotypic differences related to rs662 and rs854860 SNPs.
Answers are grounded in this paper and cite their sources.
PON1 levels and rs662 activity may inform CV risk stratification in RA; hypothesis-generating and should not yet change practice.
BACKGROUND: Atherosclerosis leading to cardiovascular disease (CVD) is the main cause of mortality and morbidity in patients with rheumatoid arthritis (RA). Paraoxonase1 (PON1) is the best understood member of plasma paraoxonases with anti-atherogenic properties. PATIENTS AND METHODS: Spanish RA (n = 549) consecutively recruited from 1 single center and 477 ethnically matched healthy controls were included in a case-control study. The concentration of PON1 was evaluated by means of an enzyme-linked immunosorbent sssay (ELISA). An arylesterase/paraoxonase assay kit was used to evaluate PON1 activity. Sample genotyping was performed by using TaqMan assays-on-demand. All results were expressed as medians ± interquartile range. One-way ANOVA comparisons were done using a nonparametric Kruskall-Wallis test. P values under 0.05 were considered to be significant. RESULTS: The concentration of PON1 in the RA group was higher than in control group (p = 0.0003), although the differences were not significant when PON1 activities were compared between both groups. No significant differences were found related to distributions of rs662 genotypes in RA patients compared to healthy controls. Among rs854860 polymorphisms, overall genotype was widely distributed between RA patients and controls. Overall PON1 concentration in plasma was not significantly different between individuals carrying any of rs662 (p = 0.8501) or rs854860 (p = 0.2741) polymorphisms. Although PON1 levels were not associated with any of the SNPs in the study, differences appear when enzyme activities are compared for each SNP separately. CVD in RA patients correlate with increased PON1 levels and lower PON1 activity. CONCLUSIONS: Although protective role of PON1 against oxidative damage in vivo could be related to other activities, in our study arylesterase activity was useful to identify phenotypic differences with emphasis placed on two SNPs coding for nonconservative amino acid changes in the functional protein.
No takes yet. Share an insight, caveat, or question.
Mucientes et al. (2018) conducted a case-control in Rheumatoid arthritis (n=1,026). Rheumatoid arthritis vs. Healthy controls was evaluated on Plasma concentration of PON1 (p=0.0003). Rheumatoid arthritis was associated with significantly higher plasma concentrations of PON1 compared to healthy controls (p=0.0003), while the rs662 polymorphism reduced PON1 enzyme activity in RA patients carrying the G allele.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: